Everything old is new again: Repurposing drugs to treat Covid-19
The practice of finding new uses for old medications — called repurposing or repositioning drugs — is not new.
The practice of finding new uses for old medications — called repurposing or repositioning drugs — is not new.
Background: Alzheimer’s disease (AD) is a chronic neurodegenerative disease needing effective therapeutics urgently. Sildenafil, one of the approved phosphodiesterase-5 inhibitors, has been implicated as having…
Posted 2:49:32 PM. The Every Cure TeamEvery Cure is a start-up, nonprofit drug development organization on a mission…See this and similar jobs on LinkedIn.
Every Cure, cofounded by Penn’s David Fajgenbaum, received a three-year $48 million federal contract to develop an AI tool for rare diseases.
Xolair cuts the risk of dangerous reactions after exposure to minute amounts of allergens, researchers reported. But children taking it still must avoid risky foods.
Celebrate Rare Disease Day 2024 in an unforgettable way with a live discussion hosted by Medidata visionaries and a special guest speaker! Dive into the…
Partnerships with the Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, and Elevate Prize Foundation Will Accelerate the Discovery of Cures Hidden on Pharmacy Shelves…
A new study highlights the possible role of an RNA molecule in explaining why women are more likely to develop autoimmune disorders than men.
David Fajgenbaum, a 32-year-old doctor at the University of Pennsylvania, is racing to find a cure for Castleman disease, an illness that’s “like a mix…
2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023.
Do you think outside the box? Or within it? David Fajgenbaum, MD, MBA, MSc promised his mother he’d become an oncologist before she passed away…